The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 2 CME credits.
Read More
Why does stroke matter in bipolar disorder? Because it’s the leading cause of death for these patients. Some mood stabilizers raise the stroke risk, while others do not.
Read More
On March 5, 2019, the FDA approved esketamine (Spravato) nasal spray as add-on therapy to traditional antidepressant medications for treatment-resistant depression (TRD). In this article, I will describe the events that led to esketamine’s development, review the data submitted to the FDA, and discuss what the future might hold for esketamine.
Read More
Certain psychiatric treatments require both the healthcare provider and patient to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program before they are administered. Here are links to enroll.
Read More
Does ginger ale treat nausea? Not really, but Dr. Mago has some better ideas, and this interview is packed with new and practical ways to manage common side effects of psychiatric medications.
Read More
When a patient presents with auditory hallucinations (AH), are you likely to diagnose a psychotic disorder? If no other symptoms are present, would you recommend an antipsychotic? If you answered yes to either question, there’s some new research that may change your mind.
Read More
Every week of depression takes a toll on infant development, so this rapid-acting treatment fills a unique need. Here we review the clinical data and the pragmatics of getting patients connected with the therapy.
Read More
Solriamfetol (Sunosi) was just approved for excessive daytime sleepiness in narcolepsy and sleep apnea, but it may have important psychiatric effects as well.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
